Tarlatamab for SCLC Brain Metastases
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorMaastricht University Medical Center
About this trial
A single arm phase II study evaluating intracranial efficacy of tarlatamab in patients with asymptomatic active brain metastases from small cell lung cancer (SCLC).
Eligibility criteria
Qualifiers
Signed and written informed consent
Age 18 years or older
Patients with pathology proven metastatic SCLC
Pretreated with at least platinum-doublet chemotherapy with or without immunotherapy, no maximum of previous lines of systemic therapy
Disqualifiers
Symptomatic BM (if asymptomatic with corticosteroids with a maximum dose of steroids of 10 mg prednisolone or equivalent/day, the patient is eligible). If in doubt, discussion with the sponsor is necessary
Leptomeningeal metastases (evaluated with MRI brain)
BM in eloquent area (to be discussed with neuro-oncologist)
Contra-indication for MRI
Trial design
Treatments tested in this trial
- Tarlatamab
Treatment groups
35 Participants
are divided into 1 treatment groupSponsors and collaborators
Maastricht University Medical Center
Lead sponsor
The Netherlands Cancer Institute
Collaborator
Erasmus Medical Center
Collaborator
University Medical Center Groningen
Collaborator
Source ClinicalTrials.gov